Abbott Laboratories stock weighs Amulet 360 data as approval remains ahead

Abbott Laboratories presented one-year results for its investigational Amulet 360 left atrial appendage occluder on November 1, 2026, at the Transcatheter Cardiovascular Therapeutics conference in San Diego. The company published the findings the following day in a Abbott press release.

The VERITAS pivotal study evaluated the next-generation device in more than 450 patients at more than 30 hospitals across the United States, Canada and Europe. Among patients assessed by transesophageal echocardiography, complete closure of the left atrial appendage, defined as zero residual leak, reached 96.3% at one year.

Clinical data strengthen the device case

Abbott said more than 98% of patients remained free from ischemic stroke or systemic embolism through one year. More than 99% avoided pericardial effusion requiring intervention, while more than 98% remained free from cardiovascular-related mortality. Major bleeding events were not reported in 93.4% of patients during the first year.

The device is designed for people with non-valvular atrial fibrillation who may need an alternative to long-term oral anticoagulation. Its redesigned lobe is intended to adapt to a wider range of left atrial appendage anatomies, while an outer disc adds a second sealing layer.

The results support Abbott's medical-device pipeline, but they do not remove the regulatory hurdle. Amulet 360 is approved for investigational use only in the United States. The device received CE Mark approval in August 2026, leaving potential U.S. clearance as an important next step for commercial expansion.

Regulatory timing remains the market focus

Because VERITAS is a pivotal single-arm study, the results establish performance at one year but do not provide a randomized comparison with oral anticoagulants or competing occluders. Longer follow-up is also needed to assess durability and clinical outcomes.

Abbott Laboratories stock traded at 99.17 euros on Lang & Schwarz at 13:10 CET on Thursday, November 12, 2026, 0.29 percent above the Xetra close of Wednesday, November 11. The comparison uses the prior Xetra session because trading was still underway in Berlin.

European healthcare shares remain sensitive to regulatory decisions and clinical readouts; investors can follow the current market environment.

Further updates on the device pipeline and Abbott Laboratories stock are available in more news and analyses on Abbott Laboratories stock.